Matthew A Gubens

Summary

Affiliation: University of California
Country: USA

Publications

  1. doi A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies
    Matthew A Gubens
    University of California, San Francisco, CA, United States Electronic address
    Lung Cancer 89:57-60. 2015
  2. doi Treatment updates in advanced thymoma and thymic carcinoma
    Matthew A Gubens
    Thoracic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    Curr Treat Options Oncol 13:527-34. 2012

Detail Information

Publications2

  1. doi A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies
    Matthew A Gubens
    University of California, San Francisco, CA, United States Electronic address
    Lung Cancer 89:57-60. 2015
    ..Src plays a role in normal thymic epithelial maturation, and its inhibition with the oral compound saracatinib was postulated to be effective in controlling thymic malignancy...
  2. doi Treatment updates in advanced thymoma and thymic carcinoma
    Matthew A Gubens
    Thoracic Oncology Program, UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA 94115, USA
    Curr Treat Options Oncol 13:527-34. 2012
    ..Greater international research collaboration, as well as modern techniques in molecular and genomic characterization, should help to advance the treatment of thymic malignancies in the near future...